Disclosures for "Oligodendrocyte Progenitor Cells Differentiation Induction with MAPK/ERK Inhibitor Fails to Support Repair Processes in the Chronically Demyelinated CNS"
-
Mr. Zveik has nothing to disclose.
-
Ms. Ganz has nothing to disclose.
-
Dr. Fainstein has nothing to disclose.
-
Mrs. Lachish has nothing to disclose.
-
Mr. Rechtman has nothing to disclose.
-
Ms. Sofer has nothing to disclose.
-
The institution of Dr. Ben-Hur has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MAPI Pharma. The institution of Dr. Ben-Hur has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kadimastem. The institution of Dr. Ben-Hur has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sipnose. The institution of Dr. Ben-Hur has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regenera Pharma. The institution of Dr. Ben-Hur has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medasense. Dr. Ben-Hur has received stock or an ownership interest from Sipnose. Dr. Ben-Hur has received stock or an ownership interest from Kadimastem. Dr. Ben-Hur has received stock or an ownership interest from MAPI Pharma. Dr. Ben-Hur has received intellectual property interests from a discovery or technology relating to health care.
-